Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enrolled in 4 early-phase trials were pooled. Rates of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Roberts, Andrew W., Ma, Shuo, Kipps, Thomas J., Coutre, Steven E., Davids, Matthew S., Eichhorst, Barbara, Hallek, Michael, Byrd, John C., Humphrey, Kathryn, Zhou, Lang, Chyla, Brenda, Nielsen, Jacqueline, Potluri, Jalaja, Kim, Su Young, Verdugo, Maria, Stilgenbauer, Stephan, Wierda, William G., Seymour, John F.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624969/
https://ncbi.nlm.nih.gov/pubmed/31023700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2018882555
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars